CMS’s Self-Developed Innovative Drug INHBE-Targeting Small Nucleic Acid Drug CMS-D008 received IND approval for Overweight/Obesity Indication

CMS-D008 is a novel siRNA therapy administered by subcutaneous injection that targets and inhibits INHBE. By loweringthe level of INHBE and its encoded Activin E protein, it can block Activin E-ALK7 signaling and reduces fat accumulation effectively. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.   Preclinical studies suggestedthat CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile, demonstrating potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass.   CMS-D008will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice […]